FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| A multicenter randomized controlled trial comparing metallic stents with 10- versus 14-mm diameter for distal biliary obstruction caused by unresectable pancreatic carcinoma. PMID 42349763 · Gastrointest Endosc · 2026-Jun-25 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. PMID 42349017 · Blood Adv · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials. PMID 42348366 · Diabetes Obes Metab · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study. PMID 42347868 · Clin Cancer Res · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment. PMID 42343061 · Eur J Clin Pharmacol · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. PMID 42341302 · N Engl J Med · 2026-Jun-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. PMID 42341301 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. PMID 42206582 · N Engl J Med · 2026-Jun-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Potassium-competitive acid blockers for erosive reflux disease and stress ulcer prophylaxis: a narrative review. PMID 42084149 · Pol Arch Intern Med · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade. PMID 41999744 · Cell · 2026-Jun-25 The record describes a secondary, exploratory biomarker analysis (gut microbiome and recurrence) from a Phase III randomized trial (CheckMate 915). While it reports on recurrence-free survival (a time-to-event endpoint) in a drug-intervention trial, it is not the primary or key secondary efficacy report of the original trial's results. The analysis is a subgroup/post-hoc biomarker study, not the formal report of the trial's primary or pre-specified secondary efficacy outcomes (e.g., overall survival or the primary comparison of nivolumab+ipilimumab vs nivolumab for recurrence-free survival). Therefore, it is excluded as not being an original formal-result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. PMID 41849227 · Blood · 2026-Jun-25 The trial is a Phase III randomized trial in oncology patients (AML/MDS) with time-to-event endpoints. However, the intervention is for GVHD prophylaxis using immunosuppressive agents (ATG, cyclophosphamide) in the transplant setting, not as a primary anticancer drug therapy. Therefore, it does not meet the criterion of a drug-containing intervention for treating malignant neoplasm. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improving basal cell carcinoma subtype diagnosis with dermoscopy and reflectance confocal microscopy: a multicentre prospective study. PMID 41685950 · Clin Exp Dermatol · 2026-Jun-25 The record describes a prospective diagnostic accuracy study for noninvasive imaging of basal cell carcinoma subtypes, not a randomized drug trial. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.), and is not a Phase III or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. PMID 42396282 · medRxiv · 2026-Jun-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Ora visual navigation course™ mobility test results in two individuals with CEP290 LCA after intravitreal injection of antisense oligonucleotide. PMID 42343659 · Ophthalmic Genet · 2026-Jun-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study. PMID 42341325 · Blood Adv · 2026-Jun-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. PMID 42340618 · Breast Cancer · 2026-Jun-24 The report is a quality-of-life analysis from a Phase III randomized trial with a drug intervention and time-to-event endpoint, but it does not present primary or key secondary time-to-event efficacy results (e.g., OS, PFS). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Minimal Clinically Important Differences to Determine Meaningful Change in the Skin Symptom Assessment (SSA) Questionnaire for the Randomized Controlled Trial of Mepitel Film Versus Standard of Care for the Prevention of Acute and Chronic Dermatitis in Breast Cancer Radiation Treatment. PMID 42431149 · Clin Breast Cancer · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials. PMID 42337097 · Pulm Ther · 2026-Jun-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management? PMID 42336749 · Eur Urol Focus · 2026-Jun-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Inhaled nitric oxide for reducing major adverse events requiring intensive life support in adults undergoing cardiac surgery with cardiopulmonary bypass: protocol for a phase III, double-blind, multicenter randomized controlled trial (NORISC Trial). PMID 42336097 · Nitric Oxide · 2026-Jun-23 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Clinical translation of an immunomodulatory cell therapy that is designed to convert "cold" tumors to "hot": A phase 2B trial in 3L MSS/pMMR metastatic colorectal cancer. PMID 42335577 · Transl Oncol · 2026-Jun-23 The trial is a Phase 2B, single-arm study. It is not randomized and is not Phase III/IIIb or Phase II/III, which are required eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage Trial in Singapore (S-CATCH): A Phase 2b, Randomized, Double-blind, Placebo-Controlled Trial. PMID 42332280 · Neurocrit Care · 2026-Jun-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod. PMID 42242900 · J Neurol Neurosurg Psychiatry · 2026-Jun-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial. PMID 42033722 · JAMA · 2026-Jun-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First. PMID 41949390 · Blood Adv · 2026-Jun-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Integration of lung tissue proteomics and genome-wide association data to identify lung cancer susceptibility proteins and potential drug targets. PMID 42396338 · medRxiv · 2026-Jun-22 The record describes a genomic/proteomic study identifying lung cancer susceptibility proteins and potential drug targets. It is not a clinical trial report and lacks the core elements of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Parathyroid Hormone Modifies the Effect of Vitamin D Supplementation on Risk of Relapse or Death in Patients with Digestive Tract Cancer: A Post Hoc Subgroup Analysis of the AMATERASU Randomized Clinical Trial. PMID 42352547 · Cancers (Basel) · 2026-Jun-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy? PMID 42333037 · Head Neck · 2026-Jun-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials. PMID 41448868 · Br J Ophthalmol · 2026-Jun-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. PMID 42323390 · Prostate Cancer Prostatic Dis · 2026-Jun-20 The report is a subgroup analysis (Black patients) from a Phase III randomized trial (ARANOTE) with a time-to-event endpoint (rPFS) and a drug intervention (darolutamide). However, it is not an original formal result report of the primary trial population; it is a pre-specified subgroup analysis. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. PMID 42323161 · Ann Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium. PMID 42321916 · Trials · 2026-Jun-20 The record describes the design of a complex clinical trial (CHIP-AML22) but is a protocol paper, not an original report of formal results. While it includes randomized comparisons and time-to-event endpoints, the Phase III status is not explicitly confirmed in the provided metadata, and the report type is 'protocol' which is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. PMID 42259343 · Lancet · 2026-Jun-20 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. PMID 42259337 · Lancet · 2026-Jun-20 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). PMID 42096662 · J Clin Oncol · 2026-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Metformin enhances the pathological response in nondiabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy: A randomized controlled trial. PMID 42456199 · J Pharmacol Exp Ther · 2026-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Smokerface poster campaign for adolescent smoking prevention in schools: A cluster-randomized controlled trial. PMID 42330568 · Eur J Cancer · 2026-Jun-19 The record describes a school-based smoking prevention trial, not a human malignant-neoplasm trial. It does not involve a drug-containing intervention or a time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Case Study on the Use of Real-World Evidence in a Feasibility Assessment of a Randomized Controlled Trial Design to Support the Fulfillment of Pediatric Requirements with the FDA and EMA. PMID 42319705 · Ther Innov Regul Sci · 2026-Jun-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema. PMID 42319677 · J Patient Rep Outcomes · 2026-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trial. PMID 42319531 · Qual Life Res · 2026-Jun-19 The record is an original secondary analysis of a randomized trial, focusing on the prognostic association between patient-reported outcomes and overall survival. It is not the primary or key secondary report of the trial's efficacy results. The phase of the trial is not explicitly stated in the provided metadata, requiring manual review for phase confirmation. The report does not meet the strict criterion of being the primary formal-result report of a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial comparing the effect of salivary substitute and fluoride varnish on radiation caries in irradiated head and neck cancer patients. PMID 42319482 · Support Care Cancer · 2026-Jun-19 The study is a randomized trial in human head and neck cancer patients, but it evaluates preventive dental interventions (salivary substitute, fluoride varnish) for radiation caries, not a drug-containing intervention for cancer treatment. The primary endpoint is DMFS score, a measure of dental decay, not a time-to-event efficacy endpoint. No Phase III/IIIb or Phase II/III designation is provided. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization Versus Transarterial Radioembolization in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trial Evidence. PMID 42352517 · Cancers (Basel) · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15-35 Years. PMID 42347661 · Vaccines (Basel) · 2026-Jun-18 The study is a Phase III randomized trial of an HPV vaccine (drug intervention) in humans with an oncology context (cancer prevention), but the primary endpoint is immunogenicity (GMT), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or analysis involving Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. PMID 42346269 · Curr Oncol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Adverse events associated with immune checkpoint inhibitors in cervical cancer: A systematic review and meta-analysis of randomized controlled trials. PMID 42320227 · Eur J Obstet Gynecol Reprod Biol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer. PMID 42315785 · Pharmacoecon Open · 2026-Jun-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol. PMID 42315278 · BMJ Open · 2026-Jun-18 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial. PMID 42313403 · JAMA Otolaryngol Head Neck Surg · 2026-Jun-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks. PMID 42313271 · Adv Ther · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage. PMID 42150044 · N Engl J Med · 2026-Jun-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |